AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04085770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 1 MCG Oral Capsule
Description: 2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay
Study NCT02593851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
Study NCT02593851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution will be administered once or twice daily for 7 days.
Study NCT04749602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 40 mg of the nivolumab will be used intrapleurally (once).
Study NCT01471522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiac catheterization
Description: Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
Study NCT01471522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary artery bypass graft surgery
Description: Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart.
Study NCT01471522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
Study NCT01471522 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: diet, physical activity, smoking cessation
Study NCT01471522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Study NCT01408966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DarkChocolate
Description: Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.
Study NCT01408966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: WhiteChocolate
Description: White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt \& Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
Study NCT01617954 — intervention group
Intervention type: DEVICE
Intervention: MammaPrint
Description: All subjects
Study NCT00712673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
Study NCT00712673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
Study NCT01336829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR/telaprevir
Description: Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
Study NCT01336829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278/telaprevir
Description: Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
Study NCT01336829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir/ETR
Description: Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
Study NCT01336829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir/TMC278
Description: Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
Study NCT00712673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT00712673 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Study NCT00712673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study NCT02586259 — intervention group
Intervention type: DRUG
Intervention: budesonide MMX®
Study NCT04544176 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: There will be no interventions in this study, it is purely observational using data already collected.
Study NCT00101608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine
Description: solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
Study NCT00712673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study NCT05839496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical stabilization exercises
Description: Patients learned the activation of deep cervical flexor and extensor muscles. Then, during the activity of deep cervical muscles, superficial cervical muscles and upper extremity muscles were also strengthened. Thus, it was aimed to strengthen all neck muscles and upper extremity muscles in different positions synchronously and to increase their endurance.
Study NCT02293304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-etch approach
Description: The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
Study NCT03913858 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Obesity Surgery with Low-Flow Anesthesia
Description: Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.
Study NCT03913858 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Obesity Surgery with High-Flow Anesthesia
Description: Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.
Study NCT03174353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Prefilled Syringe
Description: All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
Study NCT01069484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum pelvic floor muscle training
Description: Beyond a customary leaflet and thorough initial instruction on how to contract the PFM correctly, the training participants will attend one weekly supervised exercise class led by an experienced physiotherapist, and perform daily training at home. The intervention starts 6-8 weeks postpartum and last for 4 months. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum (Bø 1990, Haskell 2007). Emphasis will be on progression in force development. The participants are provided with a DVD of the program (www.corewellness.co.uk). At week 4 during the intervention, the PFM strength will be assessed for each participant. Training adherence at home will be recorded in a training diary, whereas the physical therapist will record group session adherence.
Study NCT01506271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relebactam 250 mg
Description: Relebactam 250 mg IV every 6 hours for a minimum of 96 hours
Study NCT01506271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relebactam 125 mg
Description: Relebactam 125 mg IV every 6 hours for a minimum of 96 hours
Study NCT01506271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imipenem/cilastatin
Description: A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
Study NCT01506271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Description: A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
Study NCT01506271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to relebactam
Description: Placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
Study NCT03597815 — intervention group
Intervention type: DRUG
Intervention: Aflibercept 40 MG/ML [Eylea]
Description: Intravitreal injection, form of anti-VEGF therapy
Study NCT03597815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OSA diagnostic test - overnight sleep study
Description: Overnight with specialist care in hospital - heart, lung and brain activity monitored.
Study NCT03597815 — intervention group
Intervention type: DEVICE
Intervention: CPAP therapy for OSA positive patients
Description: positive airway pressure ventilator, applies mild air pressure in a continuous basis to keep the airways continuously open in patients who are able to breath spontaneously on their own.
Study NCT04338282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: 240mg/d, every 3 weeks, for up to one year or until disease progression, whichever comes first
Study NCT02293304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse approach
Description: After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
Study NCT01813916 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: proteomic analysis
Study NCT00528957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: Tenofovir DF (oral powder or tablet): 300-mg tablets for participants > 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to > 37 kg may be switched from the oral powder to the tenofovir DF tablet.
Study NCT00528957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Zidovudine as prescribed by the investigator prior to study entry (pediatric participants \< 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
Study NCT00528957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m\^2 every 8 hours; pediatric participants > 12 years of age: 300 mg twice daily).
Study NCT00804726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Akreos MI Five-O
Description: Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
Study NCT04072926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioRoot
Description: Influence of biomaterial BioRoot on periapical healing
Study NCT04072926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioRoot
Description: Influence of biomaterial BioRoot on periapical healing
Study NCT01244685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deltex CardioQ Probe
Description: Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
Study NCT03111238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REX-001
Description: REX-001 is administered through an intra-arterial catheter.
Study NCT03111238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered through an intra-arterial catheter.
Study NCT02446184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal Cystoscopy
Description: Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
Study NCT02446184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fetal vesicoamniotic shunt
Description: Fetal vesicoamniotic shunt will be performed under ultrasound guidance
Study NCT04033562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine patch
Description: Lidocaine patch will be applied at time of Cesarean delivery for post-operative pain control.
Study NCT04033562 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr
Description: Infusion pump will be placed at time of Cesarean delivery for post-operative pain control.
Study NCT01402440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Study NCT01207635 — intervention group
Intervention type: PROCEDURE
Intervention: Ductal Lavage Fluid Collection
Description: Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.
Study NCT02955056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forsteo
Description: 20 micrograms/80 microlitres solution for injection in pre-filled pen
Study NCT00866177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00866177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given orally
Study NCT03402334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient counseling for HCV associated CVD risk factors
Description: Patients will be counseled for cardiovascular disease risk factors associated with Hepatitis C infection. Such risk factors include atherosclerosis, heart attack, and stroke. Cardiovascular risk factors can be managed through connection with primary care and reduced through curative HCV treatment.
Study NCT01422161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin commonly known as BOTOX®
Description: A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study.
Study NCT01422161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive a placebo injection.
Study NCT01129622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
Study NCT03901144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% urea/20% glycerol cream
Description: Moisturizing cream for topical application
Study NCT03901144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miniderm® 20% cream
Description: Moisturizing cream for topical application
Study NCT03901144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprobase® cream
Description: Emollient cream for topical application
Study NCT01486875 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
Study NCT00960375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BTSCS
Description: BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
Study NCT00960375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: StSST
Description: The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
Study NCT03844776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-Amoxiclav
Description: amoxicillin + clavulanic acid orally
Study NCT03844776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol orally
Study NCT03844776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: 0.2% chlorhexidine mouthwash
Study NCT03844776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline irrigation
Study NCT03844776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500 Mg
Description: Amoxicillin 500 orally
Study NCT03844776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: metronidazole 500 mg orally
Study NCT01847352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous administration of ferric carboxymaltose
Description: Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
Study NCT01847352 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Subacute hypoxic exposures
Description: Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
Study NCT04362436 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TheraSpheres Selective Internal Radiation Therapy (SIRT)
Description: Single-photon emission computed tomography (SPECT) imaging will assess 99mTc-MAA (MAA being macro aggregated albumin) deposition in the tumour bed to estimate the dose of radiation to tumour and healthy tissue, before administration of TheraSpheres to eligible patients
Study NCT02113917 — intervention group
Intervention type: BIOLOGICAL
Intervention: Identification of biological markers
Study NCT00689390 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Boceprevir
Description: In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
Study NCT00689390 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Narlaprevir
Description: In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
Study NCT00689390 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peginterferon alfa-2b
Description: In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
Study NCT00689390 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
Study NCT00689390 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood/Plasma Collection
Description: Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.